From COPD to chronic systemic inflammatory syndrome?

Lancet

Volumn 370, Issue 9589, 2007, Pages 797-799

  Fabbri, Leonardo M ^a   Rabe, Klaus F ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 34548277025     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61383-X     Document Type: Note

References (29)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD: 2006 update. Am J Respir Crit Care Med (published online May 16, 2007). DOI:10.1164/rccm.200703-456SO
2. Omori H., Nakashima R., Otsuka N., et al. Emphysema detected by lung cancer screening with low-dose spiral CT: prevalence, and correlation with smoking habits and pulmonary function in Japanese male subjects. Respirology 11 (2006) 205-210
3. Celli B., Cote C., Marin J., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
4. Mannino D., Watt G., Hole D., et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 27 (2006) 627-643
5. Yanbaeva D., Dentener M., Creutzberg E., Wesseling G., and Wouters E. Systemic effects of smoking. Chest 131 (2007) 1557-1566
6. Agusti A. Thomas A Neff lecture: chronic obstructive pulmonary disease-a systemic disease. Proc Am Thorac Soc 3 (2006) 478-481
7. Fabbri L., and Rabe K. Multiple chronic diseases. In: Proceedings of a European Respiratory Society Research Seminar. Rome, Italy; Feb 11-12, 2007. Available at: http://www.ersnet.org/ers/lr/browse/default.aspx?id=31439 (accessed Aug 8, 2007).
8. McGarvey L., John M., Anderson J., Zvarich M., and Wise R. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62 (2007) 411-415
9. Lopez A., Mathers C., Ezzati M., Jamison D., and Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006) 1747-1757
10. Kirkwood T. Understanding the odd science of aging. Cell 120 (2005) 437-447
11. Boyd C., Darer J., Boult C., Fried L., Boult L., and Wu A. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294 (2005) 716-724
12. Rutten F., Cramer M., Lammers J., Grobbee D., and Hoes A. Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur J Heart Fail 8 (2006) 706-711
13. Jorgensen N., Schwarz P., Holme I., Henriksen B., Petersen L., and Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101 (2007) 177-185
14. Marquis K., Maltais F., Duguay V., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 25 (2005) 226-232
15. Dahlstrom U. Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail 7 (2005) 309-316
16. Walker C., Zariwala M., Holness M., and Sugden M. Diet, obesity and diabetes: a current update. Clin Sci (Lond) 112 (2007) 93-111
17. Poulain M., Doucet M., Major G., et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 174 (2006) 1293-1299
18. Charlson M., Charlson R., Briggs W., and Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Gen Intern Med 22 (2007) 464-469
19. Sevenoaks M., and Stockley R. Chronic obstructive pulmonary disease, inflammation and co-morbidity: a common inflammatory phenotype?. Respir Res 7 (2006) 70
20. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 50-60
21. Broekhuizen R., Wouters E., Creutzberg E., and Schols A. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 (2006) 17-22
22. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal-joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
23. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
24. Ryden L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28 (2007) 88-136
25. Grundy S., Cleeman J., Daniels S., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
26. van der Harst P., Voors A., van Gilst W., Bohm M., and van Veldhuisen D. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 3 (2006) e333
27. Mancini G., Etminan M., Zhang B., Levesque L., FitzGerald J., and Brophy J. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47 (2006) 2554-2560
28. Sin D., and Man S. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?. Curr Opin Pulm Med 13 (2007) 90-97
29. Calverley P., Anderson J., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789